JOP20190106A1 - مثبطات أحادي أسيل جليسرول ليباز (magl) - Google Patents

مثبطات أحادي أسيل جليسرول ليباز (magl)

Info

Publication number
JOP20190106A1
JOP20190106A1 JOP/2019/0106A JOP20190106A JOP20190106A1 JO P20190106 A1 JOP20190106 A1 JO P20190106A1 JO P20190106 A JOP20190106 A JO P20190106A JO P20190106 A1 JOP20190106 A1 JO P20190106A1
Authority
JO
Jordan
Prior art keywords
magl inhibitors
compositions
magl
useful
compounds
Prior art date
Application number
JOP/2019/0106A
Other languages
English (en)
Inventor
Daniel J Buzard
Michael B Shaghafi
Cheryl A Grice
Original Assignee
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck La Jolla Research Center Inc filed Critical Lundbeck La Jolla Research Center Inc
Publication of JOP20190106A1 publication Critical patent/JOP20190106A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير كربامات بيبيرازين وتركيبات صيدلانية تشتمل على المركبات الوارد ذكرها. تكون المركبات والتركيبات موضوع الطلب مفيدة بوصفها معدلات لأحادي أسيل جليسرول الليباز (<span dir="LTR">MAGL</span>)). علاوةً على ذلك، تكون المركبات والتركيبات موضوع الاختراع مفيدة لعلاج ألم.
JOP/2019/0106A 2016-11-16 2017-06-16 مثبطات أحادي أسيل جليسرول ليباز (magl) JOP20190106A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662423099P 2016-11-16 2016-11-16

Publications (1)

Publication Number Publication Date
JOP20190106A1 true JOP20190106A1 (ar) 2019-05-09

Family

ID=62106678

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0106A JOP20190106A1 (ar) 2016-11-16 2017-06-16 مثبطات أحادي أسيل جليسرول ليباز (magl)

Country Status (29)

Country Link
US (1) US10093635B2 (ar)
EP (1) EP3541821A4 (ar)
JP (1) JP7042547B2 (ar)
KR (1) KR20190077544A (ar)
CN (1) CN110267963B (ar)
AR (1) AR110089A1 (ar)
AU (1) AU2017361251B2 (ar)
BR (1) BR112019009994A2 (ar)
CA (1) CA3043615A1 (ar)
CL (1) CL2019001339A1 (ar)
CO (1) CO2019005059A2 (ar)
CR (1) CR20190241A (ar)
DO (1) DOP2019000122A (ar)
EA (1) EA038090B1 (ar)
EC (1) ECSP19035077A (ar)
GE (1) GEP20237470B (ar)
IL (1) IL266523B (ar)
JO (1) JOP20190106A1 (ar)
MA (1) MA46857A (ar)
MX (1) MX2019005776A (ar)
NI (1) NI201900051A (ar)
PE (1) PE20191144A1 (ar)
PH (1) PH12019501097A1 (ar)
RU (1) RU2754536C1 (ar)
TN (1) TN2019000153A1 (ar)
TW (1) TWI756299B (ar)
UA (1) UA124542C2 (ar)
WO (1) WO2018093947A1 (ar)
ZA (1) ZA201903100B (ar)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY168791A (en) 2012-01-06 2018-12-04 Abide Therapeutics Inc Carbamate compounds and of making and using same
EP3294731A4 (en) 2015-05-11 2018-10-24 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
EP3515897B1 (en) 2016-09-19 2021-08-18 H. Lundbeck A/S Piperazine carbamates as modulators of magl and/or abhd6 and their use
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
BR112019010003A2 (pt) 2016-11-16 2019-08-20 Abide Therapeutics Inc formas cristalinas de um inibidor de magl
JP2020500176A (ja) 2016-11-16 2020-01-09 ルンドベック ラ ホーヤ リサーチ センター，インク． 医薬製剤
US10266497B2 (en) 2017-05-23 2019-04-23 Abide Therapeutics, Inc. Pyrazole MAGL inhibitors
PE20200664A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
MA52635A (fr) * 2018-05-15 2021-03-24 H Lundbeck As Inhibiteurs de magl
MA54827A (fr) * 2019-01-25 2022-05-04 H Lundbeck As Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl
KR20220101095A (ko) * 2019-11-15 2022-07-19 하. 룬드벡 아크티에셀스카브 Magl 억제제의 결정형
IT202000007150A1 (it) * 2020-04-03 2021-10-03 Univ Pisa Inibitori di monoacilglicerolo lipasi (magl)
CN115427403A (zh) 2020-04-21 2022-12-02 H.隆德贝克有限公司 单酰基甘油脂肪酶抑制剂的合成

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (ar) 1967-10-17 1970-06-01
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
WO1989011794A1 (en) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Plant growth inhibitor
DE69211015T2 (de) 1991-11-27 1997-01-09 Du Pont Herbizide acylierte amino-(phenyl-oder-pyridinyl-oder thienyl-)phenyl derivate
DE69408873T2 (de) 1993-12-22 1998-07-09 Shell Int Research Verfahren zur herstellung von carbamaten
AU7579696A (en) 1995-11-15 1997-06-05 Zeneca Limited Herbicidal substituted pyrazole compounds
WO1998000408A1 (en) 1996-07-02 1998-01-08 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
ATE432993T1 (de) 1999-10-04 2009-06-15 Univ New Jersey Med Tar rna bindende peptide
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
WO2005063698A1 (en) 2003-12-31 2005-07-14 Council Of Scientific & Industrial Research Process for preparing carbamates
BRPI0507499A (pt) 2004-02-18 2007-07-24 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável ou hidrato dos mesmos, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir a ativação de receptores de mglur 5
JP2008521768A (ja) 2004-12-23 2008-06-26 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式カルバミン酸誘導体、それらの製造及び医薬品としての使用
PL1836179T3 (pl) 2004-12-30 2015-10-30 Janssen Pharmaceutica Nv Pochodne amidu kwasu piperydyno- i piperazyno-1-karboksylowego oraz związki pokrewne, jako modulatory hydrolazy amidu kwasu tłuszczowego (FAAH) do leczenia lęku, bólu i innych schorzeń
US20080255150A1 (en) * 2005-11-05 2008-10-16 Astrazeneca Ab Novel Compounds
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
CA2672172C (en) 2006-12-22 2016-05-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
US7795457B2 (en) 2007-02-26 2010-09-14 Kosan Biosciences Incorporated Carbamate compounds
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
WO2010009207A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and their use as gpcr modulators
JP5576874B2 (ja) 2008-11-14 2014-08-20 ザ スクリプス リサーチ インスティテュート モノアシルグリセロールリパーゼの薬物標的化と関連する方法及び組成物
AU2010229134A1 (en) 2009-03-23 2011-11-10 Msd K.K. Novel aminopyridine derivatives having Aurora A selective inhibitory action
AR076374A1 (es) * 2009-04-22 2011-06-08 Janssen Pharmaceutica Nv Azetidinil diamidas como inhibidores de lipasas de monoacil glicerol
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
ES2433235T3 (es) 2009-11-03 2013-12-10 Bayer Intellectual Property Gmbh Fluorouretanos como aditivos en una formulación de fotopolímero
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
DK2800743T3 (en) 2012-01-06 2018-06-14 Agios Pharmaceuticals Inc THERAPEUTIC ACTIVE RELATIONS AND PROCEDURES FOR USE THEREOF
MY168791A (en) * 2012-01-06 2018-12-04 Abide Therapeutics Inc Carbamate compounds and of making and using same
WO2013142307A1 (en) 2012-03-19 2013-09-26 Abide Therapeutics Carbamate compounds and of making and using same
JP2014005245A (ja) * 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
WO2015003002A1 (en) * 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
US10570146B2 (en) * 2014-07-25 2020-02-25 Northeastern University Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof
ES2878041T3 (es) 2015-03-18 2021-11-18 H Lundbeck As Carbamatos de piperazina y métodos para prepararlos y usarlos
EP3515897B1 (en) * 2016-09-19 2021-08-18 H. Lundbeck A/S Piperazine carbamates as modulators of magl and/or abhd6 and their use
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Also Published As

Publication number Publication date
EP3541821A1 (en) 2019-09-25
AU2017361251B2 (en) 2021-08-19
KR20190077544A (ko) 2019-07-03
AU2017361251A1 (en) 2019-05-30
MX2019005776A (es) 2019-12-05
CO2019005059A2 (es) 2019-05-31
JP2020504707A (ja) 2020-02-13
US10093635B2 (en) 2018-10-09
IL266523A (en) 2019-07-31
TN2019000153A1 (en) 2020-10-05
UA124542C2 (uk) 2021-10-05
ZA201903100B (en) 2020-11-25
TWI756299B (zh) 2022-03-01
CA3043615A1 (en) 2018-05-24
PE20191144A1 (es) 2019-09-02
JP7042547B2 (ja) 2022-03-28
CN110267963B (zh) 2022-04-01
PH12019501097A1 (en) 2019-08-19
AR110089A1 (es) 2019-02-20
ECSP19035077A (es) 2019-05-31
BR112019009994A2 (pt) 2019-08-27
NI201900051A (es) 2019-10-30
IL266523B (en) 2022-09-01
CN110267963A (zh) 2019-09-20
RU2754536C1 (ru) 2021-09-03
DOP2019000122A (es) 2019-09-30
EA201991073A1 (ru) 2019-12-30
RU2019116512A (ru) 2020-12-17
TW201823216A (zh) 2018-07-01
EA038090B1 (ru) 2021-07-05
WO2018093947A1 (en) 2018-05-24
CL2019001339A1 (es) 2019-10-04
US20180134674A1 (en) 2018-05-17
MA46857A (fr) 2019-09-25
GEP20237470B (en) 2023-02-10
EP3541821A4 (en) 2020-04-22
CR20190241A (es) 2019-09-02
NZ753264A (en) 2020-12-18

Similar Documents

Publication Publication Date Title
PH12019501097A1 (en) Magl inhibitors
PH12019501102A1 (en) Magl inhibitors
PH12020551934A1 (en) Magl inhibitors
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
PH12019502646A1 (en) Pyrazole magl inhibitors
PH12019501079A1 (en) Magl inhibitors
GB2541571A (en) Pharmaceutical compositions
MY187540A (en) Compounds active towards bromodomains
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
PH12019502548A1 (en) Pyrazole magl inhibitors
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2022006862A (es) Inhibidores duales de magl y faah.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
WO2018211324A8 (en) Prodrugs for the treatment of disease
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
MX2017001512A (es) Compuestos activos hacia bromodominios.